Clinical trials: CBD
Alcohol Use Disorder
Cannabidiol in Youth Alcohol Use Disorder
The goal of this study is to test cannabidiol (CBD) as a potentially effective candidate medication for youth alcohol use disorder (AUD).
- Trial name
- NCT05317546
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Epilepsy
Cannabidiol (CBD) and Pediatric Epilepsy
Legislation to allow medical marijuana has had a significant impact on the pediatric population of Colorado. There have been many reported different effects and properties of each of the over 60 known cannabinoids found in…
- Trial name
- NCT02447198
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cannabis, Cannabis Intoxication
Do Adolescents and Adults Differ in Their Acute Response to Cannabis?
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol.
- Conditions
- Cannabis, Cannabis Intoxication, Cannabis Use, Cannabis Dependence
- Trial name
- CannTeenA (NCT04851392)
- Testing
- Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Cannabis with THC without CBD
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University College, London
CBD Exploration
CBD Repair Over T-tube or Primary Repair
the aim is to assess the benefits and harms of T-tube drainage versus primary closure without biliary stent after exploration common bile duct stones
- Trial name
- NCT04108780
- Testing
- T-tube
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Study the Efficacy of Epidiolex for Typical Absence Seizures
Epidiolex in Typical Absence Seizures
This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period…
- Trial name
- NCT04899050
- Testing
- Cannabidiol (Epidiolex)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Fragile X Syndrome
Effect of CBD on the Brain
This proposal focuses on the therapeutic relevance of the endocannabinoid (eCB) system for the treatment of Fragile-X syndrome (FXS), the primary hereditary cause of autism spectrum disorder (ASD).
- Trial name
- NCT06261450
- Testing
- CBD Oral Solution (eCBD system Target)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Cancer, Cancer (With or Without Metastasis)
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
- Trial name
- CATA (NCT07107607)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute